Impact of KIT mutation on efficacy of venetoclax and hypomethylating agents in newly diagnosed acute myeloid leukemia

Abstract Background The combination of venetoclax (VEN) with hypomethylating agents (HMAs) has emerged as a new standard treatment for older or unfit patients with acute myeloid leukemia (AML). However, the predictive factors for VEN/HMA efficacy remain unclear. In our study, we performed the first...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Wenxiu Shu, Qianqian Yang, Donghua He, Yi Li, Jing Le, Qianqian Cai, Hui Dai, Liufei Luo, Bingrong Chen, Yuan Gong, Dian Jin
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	BMC 2025-05-01
Edice:	European Journal of Medical Research
Témata:	Acute myeloid leukemia KIT Venetoclax Hypomethylating agents Chemotherapy Prognosis
On-line přístup:	https://doi.org/10.1186/s40001-025-02637-w
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!